Skip to main content

UCSF

ObGyn&RS

Gynecologic Oncology

Gynecologic Oncology Clinical Trials

The Division of Gynecologic Oncology has one of the largest Clinical Trial Research Programs in Northern California and is on the forefront of translational research in gynecologic cancers. Through the collaborative work of our providers, research team and other UCSF staff, we offer a wide variety of clinical trials that provide women with gynecologic cancers access to cutting edge investigational therapies and treatment methods. Our practice serves as a regional research hub which attracts patients from across California seeking out clinical trials. Additionally, we are a voting member of the national Cooperative Group NRG Oncology, an interdisciplinary research organization dedicated to improving the survival and quality of life of cancer patients through research, where we help to shape Gynecologic Oncology care on a national and global level. We are excited to continue to grow our Clinical Research Program by adding additional staff and expanding our trial portfolio, with the goal of being able to provide any woman with gynecologic cancer interested in participating in a clinical trial access to potentially life-saving therapy.

The following trials are currently open to accrual:

Industry Trials

  • GARNET: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors
    • Open for enrollment (MSI-H patients only)
    • NCT02715284

Cooperative Group Trials

  • NRG GY019: A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
    • Estimated to open for enrollment in December, 2019
    • NCT04095364
  • CORCEPT: A Phase 2, Randomized, Open-label, 3-arm Study of Relacorilant in Combination with Nab-Paclitaxel for Patients with Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
    • Estimated to open for enrollment in December, 2019
    • NCT03776812
       
  • NRG-GY009: A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab (IND #134427) Versus Pegylated Liposomal Doxorubicin/ Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin/ Bevacizumab in Platinum Resistant Ovarian Cancer
    • Accrual temporarily on hold for data analysis. Expected to open to Phase III portion in 2020
    • NCT02839707
       
  • NRG-GY005: A Randomized Phase II/III study of the combination of Cediranib and Olaparib compared to Cediranib or Olaparib alone, or Standard of care chemotherapy in women with recurrent platinum-resistant or -refractory ovarian, fallopian tube, or primary peritoneal cancer (COCOS)
    • Estimated to re-open at UCSF in November, 2019
    • NCT02502266

GOG Partners

  • GOG-3025: A Phase III Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of Durvalumab in Combination with Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib in Newly Diagnosed Advanced Ovarian Cancer Patients (DUO-O).
    • Estimated to open for enrollment at the end of October, 2019
    • NCT03737643
       
  • GOG-3020: ATHENA (A Multicenter, Randomized, Double-Blind, Placebo- Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy)
    • Open for enrollment
    • NCT03522246
       
  • GOG-3026: A Phase II Trial of Ribociclib (LEE011) plus Letrozole in Women with Recurrent Low-Grade Serous Carcinoma of the Ovary or Peritoneum
    • Estimated to open for enrollment at the end of September, 2019
    • NCT03673124
       
  • GOG-3018: The OVAL Study: A Randomized, Controlled, Double-Arm, Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined with Paclitaxel vs. Paclitaxel Combined with Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer
    • Estimated to open for enrollment in October, 2019
    • NCT03398655
  • GOG-3024: A Phase 1b/2 Open-Label Trial of Tisotumab Vedotin (HuMax®-TF-ADC) in Combination with Other Agents in Subjects with Recurrent or Stage IVB Cervical Cancer
    • Estimated to open for enrollment in November, 2019
    • NCT03438396
       
  • GOG-3028: A Two-arm, Randomized, Non-comparative, Phase 2 Trial of AGEN2034 (anti–PD-1) as a Monotherapy or Combination Therapy with AGEN1884 (anti-CTLA4) or with Placebo in Women with Recurrent Cervical Cancer (Second Line) – RaPiDS
    • Estimated to open for enrollment in November, 2019
    • NCT03894215

If you would like more information regarding our Gynecologic Oncology Trials at UCSF, please email our team at [email protected].

For the most recent list of clinical trials, please visit:  https://clinicaltrials.ucsf.edu.